Compare · ELV vs ISR
ELV vs ISR
Side-by-side comparison of Elevance Health Inc. (ELV) and IsoRay Inc. (ISR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and ISR operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV carries a market cap of $92.84B.
- ELV has hit the wire 10 times in the past 4 weeks while ISR has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 1 for ISR).
- Company
- Elevance Health Inc.
- IsoRay Inc.
- Price
- -
- -
- Market cap
- $92.84B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 10
- 0
- Recent ratings
- 23
- 1
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
IsoRay Inc.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Latest ELV
- AM Best Assigns Indicative Issue Credit Ratings to Elevance Health, Inc.’s New Shelf Registration
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Digital Info Ofr Lavu Ratnakar sold $572,000 worth of shares (1,300 units at $440.00), decreasing direct ownership by 8% to 14,849 units (SEC Form 4)
- SEC Form S-3ASR filed by Elevance Health Inc.
- EVP & CFO Kaye Mark sold $4,658,357 worth of shares (10,584 units at $440.13) (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Names Jeff Park President of Carelon
- SEC Form 8-K filed by Elevance Health Inc.
- Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
- The Future of Healthcare: AI-Powered, Coordinated and Proactive Care
Latest ISR
- IsoRay Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Williamson Robert F Iii bought $90,710 worth of shares (127,206 units at $0.71), increasing direct ownership by 60% to 338,761 units (SEC Form 4)
- Williamson Robert F Iii bought $78,474 worth of shares (135,879 units at $0.58), increasing direct ownership by 180% to 211,555 units (SEC Form 4)
- Puhlmann Markus bought $139,888 worth of shares (280,000 units at $0.50), increasing direct ownership by 26% to 1,375,425 units (SEC Form 4)
- Williamson Robert F Iii bought $25,478 worth of shares (51,996 units at $0.49), increasing direct ownership by 220% to 75,676 units (SEC Form 4)
- SEC Form D filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by IsoRay Inc.
- IsoRay Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 424B5 filed by IsoRay Inc.